Ikarian Capital, LLC Mustang Bio, Inc. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.58 - $1.13 $174,000 - $338,999	-300,000 Reduced 54.86%	246,824 $145,000
Q1 2022 May 13, 2022	BUY	$0.73 - $1.81 $29,777 - $73,831	40,791 Added 8.06%	546,824 $551,000
Q3 2021 Nov 15, 2021	SELL	$2.58 - $3.36 $51,522 - $67,099	-19,970 Reduced 3.8%	506,033 $1.36 Million
Q4 2020 Feb 12, 2021	SELL	$2.66 - $4.18 $746,055 - $1.17 Million	-280,472 Reduced 34.78%	526,003 $1.99 Million
Q3 2020 Nov 16, 2020	BUY	$3.01 - $3.88 $1.35 Million - $1.75 Million	450,000 Added 126.24%	806,475 $2.54 Million
Q1 2020 May 15, 2020	BUY	$1.91 - $4.52 $63,488 - $150,244	33,240 Added 10.28%	356,475 $955,000
Q4 2019 Jan 31, 2020	BUY	$2.57 - $4.08 $830,713 - $1.32 Million	323,235 New	323,235 $1.32 Million

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $20M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.